MEGAN BEGLEY: Open Payments
NPI 1992420509 · OMAHA, NE. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,032 in 72 payments from 12 companies in 2025. Trend: 2023 $1,702 · 2024 $2,438 · 2025 $2,032
Food & beverage: $2,032
| Company | Payments | Amount |
|---|---|---|
| Amgen Inc. | 14 | $440 |
| Edwards Lifesciences Corporation | 3 | $284 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 18 | $273 |
| Novartis Pharmaceuticals Corporation | 19 | $259 |
| HEARTFLOW, INC. | 2 | $218 |
| Abbott Laboratories | 1 | $160 |
| E.R. Squibb & Sons, L.L.C. | 9 | $155 |
| Alnylam Pharmaceuticals Inc. | 1 | $149 |
| PFIZER INC. | 2 | $29 |
| GlaxoSmithKline, LLC. | 1 | $27 |
Products named: REPATHA, JARDIANCE, LEQVIO, FFRct, EVOQUE, TRICLIP, AMVUTTRA, ELIQUIS.
Industry payments across NE — which companies pay providers there.
